-transparent.png){kind=logo}
In 3 patients with low-grade astrocytomas clinical pharmacology of interferon-beta (10(7) U/mg protein) was investigated. Interferon-beta with escalating dosage (2.3, 6.9, 23, 69 X 10(6) U/patient) was given to each patient in 4 infusions at weekly time intervals. In these patients dose-dependent plasma-levels of interferon-beta of up to 5800 IU/ml were achieved. Plasma concentrations showed a biphasic decline (T1 1/2:0.095-0.49 hrs and T2 1/2: 5-14.5 hrs). Side effects were: mild fatigue, myalgia, tachycardia, hypertension, and fever; the latter was well controlled by pretreatment application of paracetamol. Hematological changes included lymphopenia (2-6 hrs after infusion) and granulocytosis (3-6 hrs after infusion). Natural Killer cell activity was also monitored: 6 hours after infusion a drop of activity - not clearly dose dependent - was observed to a minimum of 1% pretreatment activity; 24 hrs after infusion activity increased up to a maximum of 400%. In this phase I study high biological activity of interferon-beta could be detected in plasma of astrocytoma patients - clinical tolerance was good and only mild toxicity was observed.
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
June 2021,
Clinical cancer research : an official journal of the American Association for Cancer Research,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
October 2014,
Neuro-oncology,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
December 1999,
Clinical cancer research : an official journal of the American Association for Cancer Research,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
June 1989,
Journal of interferon research,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
April 1987,
Journal of biological response modifiers,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
November 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
August 1995,
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
January 2023,
Neuro-oncology advances,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
March 1994,
Journal of clinical psychology in medical settings,
U Bogdahn, and
B Fleischer, and
J Hilfenhaus, and
H J Röthig, and
P Krauseneck, and
H G Mertens, and
H Przuntek
December 2004,
Haematologica,
